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Background: Replanning in intensity-modulated radiotherapy (IMRT) has been reported to improve quality of life
and loco-regional control in patients with nasopharyngeal cancer (NPC). Determination of the criteria for replanning
is, however, urgently needed. We conducted a prospective study to determine when and for what type of patients
is replanning preferred through weekly repeat computed tomography (CT) imaging during the course of IMRT.
Methods: We recruited 20 patients who were diagnosed as having loco-regionally advanced, non-metastatic stage
III or IVa NPC and treated with concurrent platinum-based chemoradiotherapy (CRT) using IMRT. Patients received
CT simulation (sim-CT) and plain magnetic resonance imaging (MRI) plus diffusion-weighted imaging (DWI) weekly
for five consecutive weeks. The gross tumor volume (GTV) and clinical target volume (CTV) were delineated and
recorded weekly based on the CT-CT fusion. The relationship between GTV/CTV reduction and clinical characteristics
of the patients were assessed using Pearson correlation test.
Results: GTV and CTV decreased during the treatment by 36.03 mL (range, 10.91–98.82 mL) and 76.79 mL (range,
33.94–125.14 mL), respectively, after 25 fractions of treatment. The percentage reductions from their initial volume
were 38.4% (range, 25.3–50.7%) and 11.8% (range, 6.7–18.3%), respectively. The greatest reductions in GTV and CTV
were observed at the fourth week (i.e., upon completion of 20 fractions), compared to pre-treatment sim-CT. Weight
loss and CTV reduction were significantly correlated with pre-treatment body mass index (BMI ) (r = 0.58, P = 0.012,
and r = 0.48, P = 0.046, respectively). However, no significant correlation was observed between CTV reduction and
initial tumor volume. In addition, GTV reduction was not significantly correlated with pre-treatment tumor volume
(P = 0.65), but negatively correlated with pre-treatment tumor apparent diffusion coefficient (ADC) values (r = −0.46,
P = 0.042).
Conclusions: Our results indicate that the most appropriate replanning time is after 20 fractions of treatment, and
pre-treatment BMI and ADC are potential predictive factors for the determination of replanning during IMRT.
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Nasopharyngeal carcinoma (NPC) is a relatively common
head and neck malignancy in southern China. The annual
crude incidence rate of NPC was reported to be 13.4 per
100,000 in Hong Kong, and the World Health Organization
(WHO) estimated 80,043 new cases per year worldwide
[1]. Numerous studies have demonstrated that intensity-
modulated radiation therapy (IMRT) can reduce radiation
toxicity and achieve better local control in patients with
NPC [2,3]. However, the optimized IMRT plan frequently
has a significant dose gradient change around the target
margin. Therefore, accuracy in the target range is essential
and is a heightened concern in the treatment plan.
The majority of NPC patients are at the locally
advanced stage at first diagnosis. Concurrent platinum-
based chemotherapy with IMRT is the standard treat-
ment for locally advanced NPC. During the course of
IMRT, especially with concurrent chemoradiotherapy
(CRT), NPC has been considered to be not only radio-
sensitive but also chemosensitive [4,5]. Most NPC pa-
tients will experience changes in anatomic structures
due to obvious tumor shrinkage and/or weight loss [6],
which leads to varying degrees of deviation in dose dis-
tributions to both tumors and organs at risk (OARs).
Recently, the importance of replanning during IMRT
has received more attention. Hansen et al. found that
the hybrid IMRT plans (without replanning) demon-
strated reduced doses to target volumes and increased
doses to critical structures, compared to IMRT with re-
planning [7]. In hybrid IMRT plans, doses up to 95% of
the planning target volumes (PTVs) for the GTV and
clinical target volume (CTV) were reduced in 92% of pa-
tients, by 0.8–6.3 Gy and 0.2–7.4 Gy, respectively. The
maximum dose to the spinal cord increased in all patients
by 0.2–15.4 Gy, and the maximum dose to brainstem in-
creased by 0.6–8.1 Gy in 85% of patients in hybrid IMRT
plans. Similar results were also reported by Height et al.
[8]. In addition, Zhao et al. [9] studied the benefits to clin-
ical outcomes from replanning and demonstrated that re-
planning could not only alleviate the late effects, but also
improve 3-year local progression-free survival.
It has been proved that replanning during IMRT is es-
sential, especially for patients receiving CRT. However,
repeat CT scan and replanning are time-consuming for
both physicians and oncologists, and not all institutes
have proper conditions to replan for every patient.
Therefore, it is important to determine when and for
what types of patients are repeated CT and replanning
preferred during IMRT. To address these questions, we
assessed the dynamic changes in GTV and CTV on
weekly repeat CT images during the course of IMRT for
loco-regionally advanced NPC patients and investigated
whether the related factors could predict the volume re-
ductions observed in this study.Methods
Study patients
Twenty consecutive patients with loco-regionally ad-
vanced NPC were enrolled in this prospective study. The
study was approved by the Ethics Committee of the First
Affiliated Hospital of College of Medicine at Zhejiang
University, and informed consent was obtained from all
participants. All 20 patients underwent an endoscopic
examination for a clinically suspected lesion in the naso-
pharynx and pathology was obtained from the primary
tumor before CRT. Subsequent staging work-up revealed
no evidence of distant metastasis in all patients.Image acquisition
Before treatment, all patients underwent head-and-neck
immobilization with thermoplastic masks (MEDTEC,
Orange City, IA) and CT simulation. All CT scans were ob-
tained on a Siemens Sensation Open scanner (Erlangen,
Germany) using 3-mm slice thickness with contrast en-
hancement. Contrast-enhanced T1- and plain T2-weighted
MRI plus diffusion-weighted imaging (DWI) were acquired
before treatment. Thereafter, all patients received sim-CT
and plain MRI plus DWI weekly for five consecutive weeks
(i.e., at the completion of 5, 10, 15, 20, and 25 fractions).Definition of target volumes
Based on the optimized CT images, one principal on-
cologist was responsible for delineating the target vol-
ume for the studied NPC patients. The GTV included
the primary lesion and cervical lymphadenopathy
shown on CT and MRI. The CTV was defined as the
GTV plus a margin of potential microscopic spread,
which included the nasopharynx, retropharyngeal
nodes, clivus, skull base, pterygoid fossae, parapharyn-
geal space, inferior sphenoid sinus, posterior third of
the nasal cavity and maxillary sinuses, and cervical lym-
phatics. The pre-treatment GTV and CTV were labeled
GTV0 and CTV0, respectively, and the following GTVs
and CTVs obtained weekly for five weeks were labeled
GTV1-5 and CTV1-5 accordingly. After weekly repeat
CT scan, CT-CT image fusions were performed be-
tween pre-treatment CT (CT0) and repeat CT images
(CT1, CT2, CT3, CT4, and CT5). The repeat CT images
were aligned to the initial treatment planning CT using
rigid bony co-registration, while accepting minor regis-
tration mismatch due to inadvertent distortional set up
discrepancy. The delineation of GTV0 and CTV0 were
then copied onto the repeat CT images. Subsequently,
the oncologist who was responsible for delineating
GTV0 and CTV0 further modified and recorded the fol-
lowing weekly GTV and CTV according to anatomical
changes and mass shrinkage.
Table 1 Comparisons of the absolute and percentage










CTV CTV0* vs CTV1 10.95 ± 1.35 1.8 8.07 <0.0001
CTV1 vs CTV2 10.91 ± 2.18 1.8 2.18 <0.0001
CTV2 vs CTV3 12.27 ± 3.17 2.9 5.44 <0.0001
CTV3 vs CTV4 23.63 ± 4.03 3.7 5.86 <0.0001
CTV4 vs CTV5 13.69 ± 2.12 2.2 6.46 <0.0001
GTV GTV0* vs GTV1 8.80 ± 1.25 10.3 7.05 <0.0001
GTV1 vs GTV2 5.98 ± 1.74 6.8 3.44 0.0027
GTV2 vs GTV3 8.79 ± 2.14 9.9 4.10 0.0006
GTV3 vs GTV4 8.01 ± 2.75 10.5 2.91 0.009
GTV4 vs GTV5 6.20 ± 0.93 9.1 6.63 <0.0001
*The pretreatment volumes were labeled week 0.
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The height and weight of each patient were obtained and
the BMI was calculated on the day of the initial planning
CT scan. The patients’ weight throughout CRT was re-
corded weekly on the same days as CT re-scanning.
The MRI studies were performed on a Philips 3.0 T
Intera Master combining a standard head coil, two-
channel dedicated surface neck coil and spine coil. DWI
was performed using the multiple-section spin-echo
single-shot echoplanar sequence in the transverse plane,
using a matrix of 96 × 96, TR/TE = 2947.1 ms/43.3 ms,
b-values of 0 and 1,500 s/mm2, FOV of 260 mm ×
260 mm, NSA of 6 times. The DWI was analyzed on a
workstation (Agfa-Gevaert, Mortsel, Belgium) by an ex-
perienced radiologist who was blind to this study. The
regions of interest (ROIs) were placed over the entire le-
sions except for obvious necrotic or cystic components
on DWI. Subsequently, apparent diffusion coefficient
(ADC) values for all ROIs were obtained directly from
an ADC map, which was reconstructed using b values of
0 and 1,500 s/mm2. Manually circumscribed ROIs were
used to quantitate the primary tumor on each slice, and
an average value for these ROIs was calculated for use as
a lesion’s final ADC value.
Treatment planning and delivery
All patients received IMRT with simultaneous integrated
boost (SIB-IMRT). A second IMRT plan was generated
from the optimized CT4 (scan at the completion of 20
fractions) to complete the planned course of treatment
though we performed weekly repeat CT scan. SIB-IMRT
was delivered to a total dose of 6540–7412 cGy/30-34 F
for planning GTV (PGTV) and 5264 cGy/28 F-6016 cGy/
32 F for PTV. All 20 patients received cisplatin 80 mg/m2
i.v. on days 1, 22, and 43 during IMRT.
Statistical analysis
Statistical analysis was performed using SAS 9.0 software
package. The differences in weight loss between BMI ≥25
and <25 groups were calculated by independent sam-
ples t test. Comparisons were made by paired t test be-
tween the volumes on the scan at a particular time
point and the scan performed on the preceding week (i.e.,
pretreatment [week 0] with week 1, week 2 with week 3,
and so on). Pearson correlation was performed to deter-
mine whether CTV reduction was related to pre-treatment
BMI and initial tumor mass, and GTV shrinkage to pre-
treatment tumor ADC and initial tumor mass. A P-value
less than 0.05 was considered statistically significant.
Results
Patient characteristics
The 20 enrolled patients included 13 men and 7 women
with a mean age of 49 years (range, 37–61 years). Eighteenpatients presented with stage III disease and 2 patients
with IVa disease according to the 7th Edition of the Ameri-
can Joint Committee on Cancer (AJCC). Histologically, 11
patients had well differentiated non-keratinizing, 4 had
poorly differentiated non-keratinizing, 4 had poorly differ-
entiated squamous cell, and 1 had unclassified carcinomas.
Of the 20 patients, the initial median weight and BMI was
60 kg (range, 50–86 kg) and 23.5 (range, 19–26.5), respect-
ively. Seven of 20 patients were overweight (BMI ≥ 25),
and the other 13 were normal weight (18.5 ≤ BMI < 25).
Weight loss of the patients
Most patients experienced significant weight loss during
the course of CRT. Compared with the baseline, mean
weight loss at treatment completion of 25 fractions was
7 kg, which corresponded to a percentage of 13.6% (range,
3.9–25.5%). Over the entire treatment course, the greatest
weight loss occurred at the end of the second week, which
corresponded to the completion of 10 fractions of radiation.
Moreover, weight loss in patients with BMI ≥ 25 was signifi-
cantly greater than that in patients with BMI < 25 (t = 3.39,
P = 0.0033), and a significant correlation was observed
between weight loss and pre-treatment BMI (r = 0.58,
P = 0.012), indicating that patients with higher BMI ex-
perience greater weight loss during CRT.
CTV changes
Compared with the baseline, mean CTV reduction after
25 fractions was 76.79 mL, corresponding to a percent-
age of 11.9% (range, 6.7–22.9%). Comparing the volume
change of each week with that of the preceding week
showed that the greatest CTV reduction of 23.63 mL
(3.7%) occurred from week 3 to week 4 (Table 1 and
Figure 1a). In addition, CTV reduction was significantly
correlated with pre-treatment BMI (r = 0.45, P = 0.047)
(Figure 2a), indicating that patients with higher BMI had a
Figure 1 Changes in CTV (a) and GTV (b) each week in 20 nasopharyngeal cancer patients during the course of CRT. CTV: clinical target
volume; GTV: gross target volume; CRT: chemoradiotherapy.
Figure 2 Pearson correlation between CTV reduction and BMI or initial tumor mass, between GTV and ADC or initial tumor mass.
(a): Correlation between BMI and CTV reduction; (b): correlation between initial tumor mass and CTV reduction; (c): correlation between
pre-treatment tumor ADC and GTV reduction; (d): correlation between initial tumor mass and GTV shrinkage. CTV: clinical target volume;
GTV: gross target volume; BMI: body mass index; ADC: apparent diffusion coefficient.
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ation between weight loss and CTV reduction during
CRT (r = 0.71, P = 0.0009). However, no significant correl-
ation was observed between CTV reduction and initial
GTV (GTV0) (Figure 2b). We compared the anatomical
structure changes on oropharyngeal and cervical slices be-
tween a patient with a BMI of 26.5 (Figure 3A) and a pa-
tient with a BMI of 19.7 (Figure 3B) when the original
CTV was contoured on oropharyngeal and cervical slices.
The anatomical structure changes, especially on cervical
slices, were much greater in the overweight patient than
in the normal weight patient.
GTV changes
Compared with pre-treatment, mean GTV shrinkage
after 25 fractions was 36.03 mL, corresponding to a per-
centage of 37.6% (range, 25.3–50.7%). The weekly abso-
lute and percentage reductions in GTV are listed in
Table 1. The two greatest percentage reductions in GTV
were 10.3% at week 1 and 10.5% at week 4 (Table 1 and
Figure 1b). GTV shrinkage was significantly correlatedFigure 3 Comparison of the anatomical structure changes in an overwe
(B): a patient with BMI = 19.7. The arrows show the obvious anatomical struc
panels show representive oropharyngeal and cervical slices at different time p
clinical target volume; CRT: chemoradiotherapy.with the pre-treatment ADC values (r = −0.46, P = 0.041)
(Figure 2c), suggesting that greater GTV reductions oc-
curred in those patients with lower initial ADCs. However,
no significant correlation was observed between GTV
reduction and pre-treatment tumor volume (P = 0.68)
(Figure 2d). Representative GTV reductions of the primary
tumor and cervical lymph nodes are shown in Figure 4.
Figure 4(A) corresponds to a patient with a tumor ADC of
0.7 × 10-3 mm/s, and Figure 4(B) corresponds to a patient
with an ADC of 0.89 × 10-3 mm/s. We observed that pa-
tients with lower tumor ADCs had relatively greater GTV
shrinkage.
Weekly changes in tumor ADC
Mean ADC values increased significantly during the first two
weeks of CRT, from 0.84 × 10-3 mm/s to 1.25 × 10-3 mm/s.
Thereafter, ADCs continued to increase and reached a
relatively flat plateau from weeks 3 to 5 (Figure 5 a).
During the last three weeks, ADCs only increased by
0.031 × 10-3 mm/s. In contrast to the ADCs, the GTVs
reduced steadily every week (Figure 5b).ight patient and a normal BMI patient. (A): a patient with BMI = 26.5;
ture changes during CRT on cervical slices. The upper and the lower
oints from week 0 to week 5, respectively. BMI: body mass index; CTV:
Figure 4 Comparison of GTV shrinkage in two patients with different tumor ADC. (A): a patient with a tumor ADC of 0.7 × 10-3 mm/s;
(B) a patient with an ADC of 0.89 × 10-3 mm/s. The arrows indicate cervical lymph node shrinkage in the patients during CRT. The upper and the
lower panels show representive primary tumor and cervical lymph node slices at different time points from week 0 to week 5, respectively.
GTV: gross target volume; ADC: apparent diffusion coefficient; CRT: chemoradiotherapy.
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In our institute, we routinely perform repeat CT and re-
planning for all NPC patients during IMRT. The time
point for replanning is generally selected at the comple-
tion of 20 or 25 fractions. However, there are still no the-
oretical data to support this. Because performing repeat
CT and replanning for each patient is time-consuming,
criteria are urgently needed for determining which pa-
tients need replanning during IMRT and when. For the
first time to the best of our knowledge, we have reported
dynamic changes in GTVs and CTVs, and their correl-
ation with potential predictive factors such as pre-
treatment tumor mass, tumor ADCs, and patient BMI in
loco-regionally advanced NPC patients undergoing IMRT.
Given that significant anatomical changes occurred
frequently from the second to the fifth week of treat-
ment based on our experience and other previous stud-
ies [8,10], we performed repeat CT scanning weekly for
five weeks during a 32- or 33-fraction IMRT. Comparing
patients with BMI ≥ 25 to patients with BMI < 25, wefound that overweight patients were more likely to ex-
perience weight loss during CRT. We speculate that
overweight patients have more cervical adipose tissue,
and therefore the neck circumference of these patients is
more easily affected by weight loss during CRT. Height
et al. reported the median weight loss post 40–50 Gy of
radiation was 3%, although all enrolled patients partici-
pated in an early nutritional intervention program to
minimize weight loss via tube feeding [8]. Because none
of the patients received tube feeding in our study, the
weight loss observed was much greater than that in the
study of Height et al. We observed a mean weight loss
of 13.6% (range, 3.9–25.5%) after five weeks of radiation.
This weight loss was considered to be associated with
the side effects of CRT, such as oropharyngeal mucositis
and gastrointestinal reactions, which were comparable
among the 20 patients and thus not taken into account
in the final analysis.
It has been recognized that most patients with head and
neck cancers receiving radiotherapy experience changes in
Figure 5 The mean absolute changes in ADC (a) values and
GTV (b). Error bars represent 95% confidence intervals. GTV: gross
target volume; ADC: apparent diffusion coefficient.
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tumors, metastatic nodal masses, and body contour caused
by profound body weight loss [7,11-14]. In the present
study, we assessed the relationship between CTV reduction
and original GTV or pre-treatment BMI and found a posi-
tive correlation between CTV reduction and BMI. This re-
sult indicates that patients with a higher BMI are more
susceptible to changes in body weight during CRTand con-
sequently experience a greater reduction in CTV. There-
fore, patients with BMI ≥ 25 should be recommended for
repeat CT scanning and replanning. However, there was no
obvious correlation between CTV reduction and original
GTV, indicating that original tumor mass probably is not a
sensitive predictor of anatomical structure changes.
Because it is obviously impractical to perform replan-
ning weekly, it is also important to determine the appro-
priate time point for replanning. We performed repeat
CT weekly and observed the most significant CTV re-
duction at the fourth week (e.g., at the completion of 20
fractions), not only in terms of absolute volume reduc-
tion but also percentage compared with the preceding
week. The peak time of this reduction is consistent with
the peak time of oropharyngeal mucositis caused by
chemoradiotherapy.We hypothesized that GTV shrinkage was most likely
related to the size of pre-treatment tumor mass (includ-
ing primary mass and metastatic lymph nodes). Interest-
ingly, we found that GTV shrinkage was not correlated
with pre-treatment GTV, but significantly correlated
with pre-treatment tumor ADC. In other words, tumor
ADC may be more sensitive than initial tumor mass for
predicting tumor shrinkage in response to CRT. DWI is
considered a functional technique because it is sensitive
to the molecular motion of water, reflecting the viability
and structure of tissue on a cellular level and providing
information about the tissue functional structure at a
microscopic level [15,16]. Many studies have demon-
strated that malignant lesions have low ADCs due to the
restriction of water molecules. A possible mechanism for
this is that hypercellularity, which corresponds to re-
duced extracellular and intracellular volume in malig-
nant lesions, inhibits water motion [17-19].
The ADC value has been used to predict and detect
tumor responses to therapy [20-23]. Kim et al. [20] in-
vestigated 33 patients with head and neck squamous cell
carcinomas who had DWI before, during, and after
CRT. They found that pre-treatment ADC value and
changes in ADC within the first week were significantly
different between complete responders and partial re-
sponders, suggesting that ADC can be used as an early
predictor of response to CRT. However, some other
studies showed that ADC at mid-treatment, instead of
pre-treatment, can predict the final tumor response
[22,23]. However, we found a negative correlation be-
tween pre-treatment ADC and percentage reduction in
GTV. One possible explanation for the above findings is
that metastatic lymph nodes were diagnosed morpho-
logically in this study as meeting the criteria of ≥1 cm in
short axis or presence of necrosis. Those metastatic
nodes with higher ADC values suggested existence of
either macroscopic or microscopic necrosis within the
lesions, which was a sign of tumor hypoxia. It is well-
known that hypoxic tumor cells are more resistant to
cytotoxic treatment including radiotherapy. Further
study is ongoing in our institute on tumor hypoxia and
treatment response using DWI and PET scan.
When replanning is performed during IMRT based on
obvious anatomic changes, it is well accepted for CTV
recontouring, but not for GTV recontouring. It remains
controversial whether GTV should be recontoured or re-
main at the initial volume when primary tumors or cer-
vical lymph nodes shrink noticeably during treatment.
Some physicians choose to maintain the original GTV
for two reasons: 1) they are unsure whether it is safe (in
terms of local-regional control) to decrease the GTV;
and 2) they have had excellent local-regional control for
head and neck cancer patients treated with IMRT in
their institutes [7,24]. However, Zhao and colleagues
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excellent local-regional control and alleviation of acute/
late toxicity due to a smaller volume of high-dose treat-
ment [9,25]. In our institute, we routinely recontour
GTV in replanning IMRT, because the tumor mass in
NPC shrinks either in a concentric (like the metastaic
cervical nodes without extracapsular extension) or a
honeycomb (like the primary lesion invading the cranial
base) manner, recontouring is needed in situation of
concentric tumor shrinkage.
In this study, an immediate and substantial increase in
ADC values was observed during the first two weeks be-
fore a relatively flat plateau was reached. Thereafter, a
smooth decline was observed in mean, absolute GTVs
during treatment (Figure 2). In comparisons of GTV re-
duction, both in absolute volumes and in percentages, at
each week relative to the preceding week, significant
changes were found at weeks 1, 3, and 4. This result sug-
gests that tumor cells begin to lose viability on the third
week, and GTV recontouring, if it is needed, should be
performed at least after the third week, although GTV
started shrinking after the first-week treatment. Consid-
ering these results in combination with the characteris-
tics of CTV changes, week 4 should be an appropriate
time for replanning during CRT.
We acknowledge that this study has several limita-
tions. First, the small sample size limited our ability to
use multivariate logistic regression models to determine
other predictive factors for replanning. Second, because
this study was performed at a single center and was rela-
tively homogeneous, multicenter and large-scale studies
are warranted.
Conclusions
Our study demonstrates that patients with high pre-
treatment BMI are more likely to experience CTV re-
duction and those with lower tumor ADCs are prone to
greater GTV shrinkage. Pre-treatment BMI and tumor
ADCs have potential as predictive factors for replanning.
Moreover, this study also suggests that the most appro-
priate replanning time is after 20 fractions of treatment.
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